Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a rare but severe complication affecting patients receiving antiresorptive and/or biological therapy influencing bone metabolism. Moreover, the increasing use of these drugs and introduction of high-risk medicines increases the incidence of this condition.
The therapy is sometimes very difficult, often lengthy and, so far, without clear consensus among experts. However, recent findings suggest that in the management of osteonecrosis of the jaw, better results are achieved with radical surgical therapy than a conservative approach.
Surgical therapy should be indicated as early, regardless of the disease stage; if this way of treatment is contraindicated, the conservative approach is reasonable. The most important strategy, however, is compliance with preventive measures and interdisciplinary cooperation.
In their paper, the authors provide an overview of the current options for the diagnosis, staging and treatment of MRONJ.